Latest Information Update: 24 Aug 2009
At a glance
- Originator GTx
- Mechanism of Action Selective androgen receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cachexia
Most Recent Events
- 24 Aug 2009 Discontinued - Phase-I for Cachexia in USA (PO)
- 19 Mar 2004 GTx and Ortho Biotech have entered into a joint collaboration, license and Co-promotional agreement for andarine worldwide for Mens Health
- 04 Mar 2004 Three phase I clinical studies have been completed